TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20303577

Group type: EXPERIMENTAL
Intervention: Uroflowmetry biofeedback
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Biofeedback training of the pelvic floor muscles
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Uroflowmetry biofeedback combined with biofeedback training of the pelvic floor muscles
Number of subjects: 86

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 86
Study: 18051616

Group type: EXPERIMENTAL
Intervention: Triple P parent training
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 280
Study: 15584064

Group type: EXPERIMENTAL
Intervention: Oral nifedipine 20 mg twice daily
Number of subjects: 77

Group type: COMPARATOR
Intervention: Topical 0.2 percent glyceryl trinitrate ointment
Number of subjects: 77
Study: 11903078

Group type: EXPERIMENTAL
Intervention: Epidural PCA with bupivacaine 0.06% and sufentanil 1 microg x ml(‐1)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Intrathecal morphine 0.15 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Epidural PCA
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 53
Study: 9619712

Group type: EXPERIMENTAL
Intervention: Goserelin (3.6 mg subcutaneously every 4 weeks)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Goserelin plus mitomycin (14 mg/m2 i.v. every 6 weeks)
Number of subjects: 63
Study: 7702998

Group type: EXPERIMENTAL
Intervention: + (R)-thalidomide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: - (S)-thalidomide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Racemate thalidomide
Number of subjects: 0
Study: 2711155

Group type: EXPERIMENTAL
Intervention: Ketanserin monotherapy
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Ketanserin with hydrochlorothiazide/amiloride
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Ketanserin with atenolol
Number of subjects: 188

Group type: COMPARATOR
Intervention: Ketanserin
Number of subjects: 188
Study: 901134

Group type: EXPERIMENTAL
Intervention: Group therapy intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group therapy intervention (second year participants)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Target symptoms
Number of subjects: 0
Study: 31658111

Group type: EXPERIMENTAL
Intervention: Virtual reality intervention in addition to Traditional Occupational Therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Traditional Occupational Therapy
Number of subjects: 90
Study: 30007942

Group type: EXPERIMENTAL
Intervention: Two-thumb-encircling technique
Number of subjects: 16

Group type: COMPARATOR
Intervention: Two-finger technique
Number of subjects: 16
Study: 27965005

Group type: EXPERIMENTAL
Intervention: Gamepad (experimental group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Physiotherapy without biofeedback (control group)
Number of subjects: 42
Study: 25434635

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg/day
Number of subjects: 940

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 940
Study: 24241277

Group type: EXPERIMENTAL
Intervention: Nursing consultations (nurse-delivered consulting home visits and follow-up telephone calls)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (nonequivalent control group)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Nursing consultations
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study: 21717984

Group type: EXPERIMENTAL
Intervention: High tibial osteotomy plus microfractures (Group A; n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: High tibial osteotomy alone (Group B; n=20)
Number of subjects: 40
Study: 19400831

Group type: EXPERIMENTAL
Intervention: 0.1% copper-zinc malonate-containing cream applied twice daily
Number of subjects: 21
Study: 16707551

Group type: EXPERIMENTAL
Intervention: Exercise plus low-carbohydrate diet (Ex+Lo CHO)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Low-carbohydrate diet alone (Lo CHO)
Number of subjects: 9
Study: 14750756

Group type: EXPERIMENTAL
Intervention: 0.3 mg/mL of adjunctive mitomycin C for 3 minutes
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no MMC)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups (MMC and control)
Number of subjects: 26
Study: 10693993

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (45/6.4 mg/kg/day in two divided doses for 10 days)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Azithromycin (10 mg/kg on Day 1, then 5 mg/kg daily on Days 2 through 5)
Number of subjects: 238
Study: 9141110

Group type: EXPERIMENTAL
Intervention: Ultrasonic nebulizers (UltraNeb 99/100, UltraAIR, Aerosonic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Jet nebulizers (Dura ProNeb, Pari‐LL, Sidestream, Marquest Acorn II, Hudson T Updraft II, Baxter MistyNeb, Pari‐LC, Pari IS‐2, disposable Sidestream)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrasonic devices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Jet nebulizers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Jet nebulizers and ultrasonic devices
Number of subjects: 0
Study: 9114916

Group type: EXPERIMENTAL
Intervention: GR 32191 (20 mg and 40 mg, orally)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3080882

Group type: EXPERIMENTAL
Intervention: Prazosin (1 to 8 mg per day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propranolol (40 to 240 mg per day)
Number of subjects: 10
Study: 3351815

Group type: EXPERIMENTAL
Intervention: Danazol treatment (6-month course)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Untreated group (no treatment)
Number of subjects: 73
Study: 30731474

Group type: EXPERIMENTAL
Intervention: Linaclotide (290 μg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: PEG (historical control)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Linaclotide
Number of subjects: 29

Group type: COMPARATOR
Intervention: PEG
Number of subjects: 29
Study: 28295221

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25462898

Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24592760

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no tranexamic acid)
Number of subjects: 100
Study: 21504624

Group type: EXPERIMENTAL
Intervention: B/B Checker®
Number of subjects: 30
Study: 18242811

Group type: EXPERIMENTAL
Intervention: E group (n=32)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: E-P group (n=29)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (n=31)
Number of subjects: 92
Study: 15843503

Group type: EXPERIMENTAL
Intervention: Subliminal attentional bias to pain-related words
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Supraliminal attentional bias to pain-related words
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Subliminal attentional bias to social threat-related words
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Supraliminal attentional bias to social threat-related words
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Attentional biases
Number of subjects: 59
Study: 12946516

Group type: EXPERIMENTAL
Intervention: Sonography of the elbow joint
Number of subjects: 320
Study: 10999495

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine at 1 atm
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine at 3 atm
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo at 1 atm
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo at 3 atm
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Depth at 3 atm
Number of subjects: 30
Study: 9186345

Group type: EXPERIMENTAL
Intervention: Nilutamide plus orchiectomy
Number of subjects: 457

Group type: COMPARATOR
Intervention: Placebo plus orchiectomy
Number of subjects: 457
Study: 1307883

Group type: EXPERIMENTAL
Intervention: Closed method of drawing blood from arterial lines (n = 784)
Number of subjects: 1657

Group type: COMPARATOR
Intervention: Open method of drawing blood from arterial lines (n = 873)
Number of subjects: 1657
Study: 3839796

Group type: EXPERIMENTAL
Intervention: Prostaglandin inhibitor (naproxen sodium)
Number of subjects: 139
Study: 31862147

Group type: EXPERIMENTAL
Intervention: Flash glucose monitoring
Number of subjects: 299

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 299
Study: 29335014

Group type: EXPERIMENTAL
Intervention: Late parenteral nutrition (PN)
Number of subjects: 1343

Group type: COMPARATOR
Intervention: Early parenteral nutrition (PN)
Number of subjects: 1343
Study: 27323697

Group type: EXPERIMENTAL
Intervention: PEEP (4 cm H2O)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No PEEP (0 cm H2O)
Number of subjects: 25
Study: 23592317

Group type: EXPERIMENTAL
Intervention: Vitamin C (1,000 mg) and Vitamin E (400 IU)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 22909282

Group type: EXPERIMENTAL
Intervention: P. ginseng extract (1 g/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P. ginseng extract (2 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19785625

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Pantoprazole 40 mg
Number of subjects: 19
Study: 19076084

Group type: EXPERIMENTAL
Intervention: 1.5 mg of indapamide retard with or without addition of 2‐4 mg of perindopril
Number of subjects: 3845
Study: 16826016

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 22
Study: 12486423

Group type: EXPERIMENTAL
Intervention: Lamifiban with LMWH
Number of subjects: 5200

Group type: COMPARATOR
Intervention: UFH
Number of subjects: 5200

Group type: EXPERIMENTAL
Intervention: LMWH
Number of subjects: 5200
Study: 10543284

Group type: EXPERIMENTAL
Intervention: Nebulized furosemide (40 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 8550646

Group type: EXPERIMENTAL
Intervention: Baseline immunosuppressive doses of glucocorticoids (10 mg of prednisone)
Number of subjects: 28
Study: 2141247

Group type: EXPERIMENTAL
Intervention: Mammalian cell-derived recombinant DNA hepatitis B vaccine (Betagen)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Plasma-derived vaccine (Heptavax-B)
Number of subjects: 800
Study: 6109234

Group type: EXPERIMENTAL
Intervention: Phloctaphenin (200 mg)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) (200 mg)
Number of subjects: 78
Study: 31948452

Group type: EXPERIMENTAL
Intervention: Comprehensive Sexual and Reproductive Health Education (CSRHE) youth clubs
Number of subjects: 0
Study: 29166321

Group type: EXPERIMENTAL
Intervention: 75 g low glycemic index modified starch supplement (UCAN)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 75 g high glycemic index glucose‐based supplement (G)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Flavor‐matched noncaloric placebo (PL)
Number of subjects: 10
Study: 27421617

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy delivered by telephone (CBT-T)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Telephone-delivered nondirective supportive therapy (NST-T)
Number of subjects: 141
Study: 25386945

Group type: EXPERIMENTAL
Intervention: Common Elements Treatment Approach (CETA) delivered by lay counselors
Number of subjects: 347

Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: CETA
Number of subjects: 347

Group type: COMPARATOR
Intervention: WLC
Number of subjects: 347
Study: 22852878

Group type: EXPERIMENTAL
Intervention: Proactive multi-session telephone counseling with motivational enhancement delivered by study staff
Number of subjects: 0

Group type: COMPARATOR
Intervention: Faxed or online referral to the New York State Quitline
Number of subjects: 0
Study: 19936725

Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg
Number of subjects: 2701

Group type: EXPERIMENTAL
Intervention: Tocilizumab 4 mg/kg
Number of subjects: 2701
Study: 16899484

Group type: EXPERIMENTAL
Intervention: PATHOZYME‐TB Complex Plus commercial ELISA kit measuring immunoglobulin G against 38‐kDa and 16‐kDa recombinant antigens
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control group (healthy volunteers and subjects with pulmonary diseases other than TB)
Number of subjects: 179
Study: 15609278

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colestimide
Number of subjects: 0
Study: 12175357

Group type: EXPERIMENTAL
Intervention: Foam swabs
Number of subjects: 34

Group type: COMPARATOR
Intervention: Toothbrushes
Number of subjects: 34
Study: 9570255

Group type: EXPERIMENTAL
Intervention: Prednisolone metasulphobenzoate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hydrocortisone acetate
Number of subjects: 24
Study: 7756935

Group type: EXPERIMENTAL
Intervention: Gonozyme enzyme immunoassay
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Gonozyme enzyme immunoassay (urine)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Gonozyme enzyme immunoassay (swabs)
Number of subjects: 42
Study: 3195535

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (32 subjects)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Limited exertion program (37 subjects)
Number of subjects: 98
Study: 29976173

Group type: EXPERIMENTAL
Intervention: Point-of-care Circulating Cathodic Antigen (POC-CCA) test integrated with praziquantel (PZQ) treatment.
Number of subjects: 450

Group type: COMPARATOR
Intervention: Praziquantel (PZQ) treatment without testing.
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Point-of-care Circulating Cathodic Antigen (POC-CCA) test.
Number of subjects: 450
Study: 27700210

Group type: EXPERIMENTAL
Intervention: Boron-based gel
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 26159834

Group type: EXPERIMENTAL
Intervention: Immersive smartphone app
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Non-immersive smartphone app
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual behavior (control)
Number of subjects: 51
Study: 22788723

Group type: EXPERIMENTAL
Intervention: AR-NT (no surface treatment)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AR-CO (surface silicatization with CoJet sand)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AR-ZP (zirconia surface treated with Z-Prime Plus)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AG-CO (surface silicatization with CoJet sand)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AG-ZP (zirconia surface treated with Z-Prime Plus)
Number of subjects: 30

Group type: COMPARATOR
Intervention: AR (as received, control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AG (artificial aging)
Number of subjects: 30
Study: 21492364

Group type: EXPERIMENTAL
Intervention: Rivoglitazone 0.5 mg daily
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Rivoglitazone 1.0 mg daily
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Rivoglitazone 1.5 mg daily
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg daily
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Rivoglitazone 1.0 mg and 1.5 mg
Number of subjects: 287
Study: 19797185

Group type: EXPERIMENTAL
Intervention: Extended Parallel Process modified poster
Number of subjects: 274

Group type: COMPARATOR
Intervention: Standard educational poster (control)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Both posters (younger group)
Number of subjects: 274
Study: 16377048

Group type: EXPERIMENTAL
Intervention: Alcohol challenge
Number of subjects: 22

Group type: COMPARATOR
Intervention: No-alcohol
Number of subjects: 22
Study: 15609596

Group type: EXPERIMENTAL
Intervention: Self-prepared ear-dropping made by combined Chinese and Western drugs
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo ear-dropping
Number of subjects: 64
Study: 11067720

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoxetine and Paroxetine
Number of subjects: 0
Study: 9511077

Group type: EXPERIMENTAL
Intervention: Quinupristin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dalfopristin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinupristin and dalfopristin (combined)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinupristin/dalfopristin
Number of subjects: 0
Study: 8638859

Group type: EXPERIMENTAL
Intervention: 20% benzocaine gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Belief manipulation (active agent vs placebo)
Number of subjects: 0
Study: 2513966

Group type: EXPERIMENTAL
Intervention: Oral diazepam elixir (0.3 mg/kg)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Intramuscular papaveretum with hyoscine (0.3 mg/kg with 0.006 mg/kg)
Number of subjects: 151

Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 151
Study: 166586

Group type: EXPERIMENTAL
Intervention: Cytarabine (50 mg/m² body surface area, subcutaneously, once daily for 4 days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cytarabine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31624391

Group type: EXPERIMENTAL
Intervention: CT three-dimensional reconstruction technique for guiding tracheal intubation (group E)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rigid fiber bronchoscopes shaped according to CT images (group E)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Rigid fiber bronchoscopes with original angles (group C)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CT three-dimensional reconstruction technique (group E)
Number of subjects: 44
Study: 28538759

Group type: EXPERIMENTAL
Intervention: CVP maintained ≤ 15 cmH2O (G15)
Number of subjects: 140

Group type: COMPARATOR
Intervention: CVP maintained ≤ 20 cmH2O (G20)
Number of subjects: 140
Study: 24633388

Group type: EXPERIMENTAL
Intervention: Antiplatelet and antithrombotic therapy (AP/AT)
Number of subjects: 5211

Group type: COMPARATOR
Intervention: No antiplatelet and antithrombotic therapy (AP/AT)
Number of subjects: 5211
Study: 22223598

Group type: EXPERIMENTAL
Intervention: 10 mg hyoscine‐N‐butylbromide
Number of subjects: 816

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Both groups (hyoscine‐N‐butylbromide and placebo)
Number of subjects: 816
Study: 20100962

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 435
Study: 17869448

Group type: EXPERIMENTAL
Intervention: d-threo-methylphenidate HCl (d-MPH)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 15859527

Group type: EXPERIMENTAL
Intervention: Additional backward walking training (30 min, three times a week for three weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional training programme (40 min, three times a week for three weeks)
Number of subjects: 25
Study: 12556949

Group type: EXPERIMENTAL
Intervention: Actimel (fermented milk preparation)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Indian Dahi (fermented milk preparation)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Ultra-heat-treated yoghurt preparation (control group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Actimel as a starter in community
Number of subjects: 150
Study: 10354807

Group type: EXPERIMENTAL
Intervention: Rapid Serial Visual Presentation (RSVP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RSVP with a completion meter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sentence-by-sentence presentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sentence-by-sentence presentation with a completion meter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal page condition
Number of subjects: 0
Study: 8733313

Group type: EXPERIMENTAL
Intervention: Nutritional supplement (1000 kcal/day, casein based enteral nutritional formula)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (using pressure threshold load valve at 30% of Maximal Inspiratory Mouth Pressure) with nutritional supplement
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (using pressure threshold load valve) without nutritional supplement
Number of subjects: 23

Group type: COMPARATOR
Intervention: No training or nutritional supplement
Number of subjects: 23
Study: 2665800

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Betamethasone (3 injections or more)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo (3 injections or more)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Betamethasone (24h to 6 days after entry)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo (24h to 6 days after entry)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Betamethasone (before 34 weeks gestation, 3 injections or more)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo (before 34 weeks gestation, 3 injections or more)
Number of subjects: 262
Study: 339045

Group type: EXPERIMENTAL
Intervention: +Cyanidanol-3
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 31631058

Group type: EXPERIMENTAL
Intervention: Alpha-synchronized rTMS
Number of subjects: 17

Group type: COMPARATOR
Intervention: Modified iTBS
Number of subjects: 17

Group type: COMPARATOR
Intervention: Random alpha phase control condition
Number of subjects: 17
Study: 30664539

Group type: EXPERIMENTAL
Intervention: Combined Cognitive Processing Therapy (CPT) and smoking cessation treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Smoking cessation treatment without CPT
Number of subjects: 40
Study: 29211128

Group type: EXPERIMENTAL
Intervention: Whiteness HP ‐ FGM (35% hydrogen peroxide)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Whiteness HP Blue Calcium ‐ FGM (35% hydrogen peroxide)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Whiteness HP Blue Calcium ‐ FGM (20% hydrogen peroxide)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 53